Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

Explore the causes of itching in liver diseases and tips to relieve discomfort. Learn about treatments for pruritus and when ...

Pruritus is a common symptom that can significantly impair ... U.S. Indication for Livdelzi Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ...

The most common symptoms of PBC are pruritus (chronic itch) and fatigue, which can be debilitating for some people. There is currently no cure for PBC and treatment goals include slowing disease ...

Pruritus is a common symptom that can significantly ... U.S. Indication for Livdelzi Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ...

culminating in immune-mediated damage to the biliary epithelial cells. Predominantly afflicting middle-aged women, PBC manifests most commonly through fatigue and pruritus. Diagnostic laboratory ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat patients with the rare liver disease primary biliary cholangitis ... and is ...

February 20, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Volixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in 2026. LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis ... meaningful reduction in itching (pruritus) – one of the ...